Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro

Barnes, James L.; Barnes, Nicholas M.; Costall, B.; Horovitz, Zola P.; Naylor, R.J.

doi:10.1016/0006-8993(89)90095-4

Cited by 83 publications

(40 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…60 High levels of angiotensin II have also been shown to inhibit acetylcholine release in rats and humans. 61,62 Hence, it may be considered that ACEIs and ARBs decrease the effect of the angiotensin II which may reduce the inhibitory action on acetylcholine release and thereby increase acetylcholine concentration. It has been demonstrated that stimulation of the RAS causes activation of inflammatory cytokines that may play a vital role in degenerative dementias.…”

Section: Discussionmentioning

confidence: 99%

Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property

Singh

Sharma

Jaggi

et al. 2012

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

This study investigates the beneficial role of lisinopril, an angiotensin converting enzyme inhibitor (ACEI) and telmisartan, an angiotensin receptor blocker (ARB), in intracerebroventricular (i.c.v.) streptozotocin (STZ) induced dementia of Alzheimer's disease (AD) type in mice. This study also aimed to explore the role of PPAR-γ in lisinopril and telmisartan mediated effects in i.c.v. STZ mice. Donepezil served as the positive control in the study. Mice underwent i.c.v. injection of STZ. The Morris water maze (MWM) test was employed for assessment of learning and memory. Various biochemical estimations, namely brain acetylcholinesterase (AChE) activity, myeloperoxidase (MPO) activity, nitrite/nitrate and thiobarbituric acid reactive species (TBARS) levels and reduced glutathione (GSH) levels, were also performed. The study showed that i.c.v. STZ significantly impaired learning and memory of the animals along with a significant enhancement in brain AChE, MPO, TBARS, nitrite/nitrate levels and reduction in brain GSH levels. Treatments of lisinopril/telmisartan/ donepezil significantly attenuated STZ induced behavioral and biochemical changes. Pre-treatment with bisphenol-Adiglycidyl ether (BADGE), a selective PPAR-γ antagonist, significantly abolished the beneficial effect of lisinopril/telmisartan in i.c.v. STZ treated animals. The results of this investigation document a potential role of PPAR-γ in the beneficial effects of lisinopril and telmisartan in i.c.v. STZ dementia of AD type.

show abstract

Section: Discussionmentioning

confidence: 99%

Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property

Singh

Sharma

Jaggi

et al. 2012

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

show abstract

“…Moreover, AT 1 -receptor blockers may help to maintain or even improve cognitive function through mechanisms other than blood pressure (BP) reduction. In experimental models of cognitive function, angiotensin II has been shown to impair performance in learning and memory paradigms, which appears to be the result of angiotensin II-induced inhibition of acetylcholine release [31]. Animal studies have also shown that treatment with the AT 1 -receptor blocker losartan can improve cognitive performance [32].…”

Section: Rationale For Proposed Studymentioning

confidence: 99%

The Study on Cognition and Prognosis in the Elderly (SCOPE)

Lithell¹,

Hansson²,

Skoog

et al. 2003

Journal of Hypertension

1,259

194

View full text Add to dashboard Cite

. Study on cognition and prognosis in the elderly (SCOPE). Blood Pressure 1999; 8: 177-183.The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multicentre, prospective, randomized, double-blind, parallel-group study designed to compare the effects of candesartan cilexetil and placebo in elderly patients with mild hypertension. The primary objective of the study is to assess the effect of candesartan cilexetil on major cardiovascular events. The secondary objectives of the study are to assess the effect of candesartan cilexetil on cognitive function and on total mortality, cardiovascular mortality, myocardial infarction, stroke, renal function, hospitalization, quality of life and health economics. Male and female patients aged between 70 and 89 years, with a sitting systolic blood pressure (SBP) of 160-179 mmHg and/or diastolic blood pressure (DBP) of 90-99 mmHg, and a Mini-Mental State Examination (MMSE) score of 24 or above, are eligible for the study. The overall target study population is 4000 patients, at least 1000 of whom are also to be assessed for quality of life and health economics data. After an open run-in period lasting 1-3 months, during which patients are assessed for eligibility and those who are already on antihypertensive therapy at enrolment are switched to hydrochlorothiazide 12.5 mg o.d., patients are randomized to receive either candesartan cilexetil 8 mg once daily (o.d.) or matching placebo o.d. At subsequent study visits, if SBP remains b160 mmHg, or has decreased by`10 mmHg since the randomization visit, or DBP is b85 mmHg, study treatment is doubled to candesartan cilexetil 16 mg o.d. or two placebo tablets o.d. Recruitment was completed in January 1999. At that time 4964 patients had been randomized. All randomized patients will be followed for an additional 2 years. If the event rate is lower than anticipated, the follow-up will be prolonged.

show abstract

“…9,10 Brain angiotensin II (Ang II) and its fragments Ang IV and Ang III have been shown to influence performance in learning and memory paradigms directly or by modulating the activity of other neurotransmitters, like acetylcholine, catecholamines, serotonin and other peptides. [11][12][13] Beyond being implicated in neuronal functions regulation, these neurotransmitters also regulate local vasomotility and endothelium-dependent relaxation, which is of relevance for maintaining the physiological self-regulation of brain flow, that is presumed to be necessary to correct performance of cerebral functions. 14 Owing to the role of the RAS in modulating cognitive processes, drugs that interfere with the RAS like angiotensin-converting enzyme inhibitors (ACE-I) and Ang II AT1 receptor blockers (ARB) possess the potential of preventing cognitive decline and even improving cognitive function in hypertensive patients.…”

Section: Introductionmentioning

confidence: 99%

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients

et al. 2005

View full text Add to dashboard Cite

The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/ HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP) 490 mmHg and o110 mmHg and systolic blood pressure (SBP) 4140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d. or lisinopril 20 mg/HCTZ 12.5 mg o.d. for 24 weeks, according to a prospective, open-label, blinded end point, parallelgroup design. At the end of a 2-week wash-out period and after 12 and 24 weeks of active treatment, 24-h noninvasive ambulatory BP monitoring (ABPM) was performed and cognitive function was evaluated through six different tests (verbal fluency, Boston naming test, word-list memory, word-list recall, wordlist recognition and Trails B). Both treatments significantly reduced ambulatory BP. However, the telmisartan/HCTZ combination produced a greater reduction in 24-h, day-time and night time ABPM values. Lisinopril/ HCTZ did not induce significant changes in any of the cognitive function test scores at any time of the study, whereas at both 12 and 24 weeks telmisartan/HCTZ significantly improved the word-list memory score ( þ 17.1 and þ 15.7%, respectively, Po0.05 vs baseline), the word-list recall score ( þ 13.5 and þ 16.9%, Po0.05) and the Trails B score (À33 and À30.5%, Po0.05). These results suggest that in elderly hypertensive patients treatment with telmisartan/HCTZ produces a slightly greater reduction in ambulatory BP than lisinopril/HCTZ combination and, unlike this latter, improves some of the components of cognitive function, particularly episodic memory and visuospatial abilities.

show abstract

Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro

Cited by 83 publications

References 20 publications

Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property

Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property

The Study on Cognition and Prognosis in the Elderly (SCOPE)

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients

Contact Info

Product

Resources

About